Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has been effective diligently but unsuccessfully to develop a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be used is actually an open question.

While CYDY  is actually dawdling, market opportunities for leronlimab as a combination treatment in the curing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of the past several shares of mine. My first CytoDyn post, “CytoDyn: What to be able to Do When It is Too Good To Be True?”, set out all of the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan presented such a highly marketing image in the Uptick Newswire interview which I came away with an inadequate impression of the business.

Irony of irony, the poor impression of mine of the company has grown steadily, though the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the treatment and prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s payment of $3.5 million transfers ownership of the expertise and also associated intellectual property coming from Progenics to CytoDyn, as well as roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 huge number of) and the very first new drug program approval ($5 million), and also royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with numerous indications and numerous therapies, it has this single treatment in addition to a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a likely advantageous therapy in dozens of indications.

The opening banner of its on the website of its (below) shows an energetic business with diverse interests albeit focused on leronlimab, several disease types, multiple presentations and multiple publications.

Can all of it be smoke and mirrors? That’s a question I’ve been asking myself through the really beginning of my interest in this organization. Judging by the multiples of a huge number of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am far from alone in this particular question.

CytoDyn is a traditional battleground, or perhaps some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *